EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor
Philadelphia, PA, – NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the
Leucid Bio: the next generation of CAR T-cell therapies
CAR T-cell therapies hold the promise of curing solid tumour cancers. Dr John Maher, Chief Scientific Officer of Leucid Bio, explains how his biotech is
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
WALTHAM, Mass., — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300
Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize
Southampton, UK – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and small molecule drugs to
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796
Pioneering small-molecule program, NT-0796, targets chronic inflammation and its fundamental role in the complex cycle of weight regulation Oral, brain-penetrant NLRP3 inflammasome inhibitor being investigated
Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
• Initiation of AERIAL trial accelerated by successful first close of Series A1 financing• LEU011 is first CAR-T candidate for the treatment of solid tumours
RapidPulse Announces Patient Enrollment Initiated in Pivotal Ischemic Stroke Study
May 06, 2025 11:00 ET | Source: RapidPulse, Inc MIAMI, May 06, 2025 (GLOBE NEWSWIRE) — RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on